Kids' HIV drug gets extended safety check
NCT ID NCT02494986
Summary
This study provides continued access to the HIV medication rilpivirine for children who previously took it in earlier trials and are benefiting from it. Researchers will monitor 48 children with HIV-1 for up to 4 years to track long-term safety while they continue taking the medication alongside other HIV drugs. The goal is to gather more safety information about extended use of this treatment in young patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Porto, Portugal
-
Study site
Bloemfontein, South Africa
-
Study site
Dundee, South Africa
-
Study site
Esplugues de Llobregat, Spain
-
Study site
Bangkok, Thailand
-
Study site
Nonthaburi, Thailand
-
Study site
Entebbe, Uganda
-
Study site
Kampala, Uganda
Conditions
Explore the condition pages connected to this study.